Rob Dillard

DocwireNews

<p>Four of 6 children born with HIV who were deemed eligible to have their treatment paused have remained free of detectable disease for over a year, according to the findings of an ongoing study presented this month at the Conference on Retroviruses and Opportunistic Infections in Denver, Colorado.<p>Children infected with HIV in utero, during birth, or through breastmilk must undergo lifelong antiretroviral therapy (ART) to prevent the virus&rsquo; ability to replicate, thereby preventing life-threatening complications. ART medications&mdash;which are given in liquid form to children&mdash;are a huge burden on families due to their unpleasant flavor, frequency of dosing, and rigid schedule. Moreover, ART medications are costly and come with a plethora of side effects.</p><h2><strong>Importance of &lsquo;The Mississippi Baby&rsquo;</strong></h2><p>Historically, an interruption in treatment has led to resumed HIV replication and detectable virus in the blood within weeks, according to researchers. However, in 2013, a case study known as &ldquo;The Mississippi Baby&rdquo; described an infant born with HIV in Mississippi who initiated ART treatment at 30 hours of life, was taken off ART at 18 months of age, and remained in remission with no evidence of detectable HIV for 27 months.</p><p>&ldquo;This is the first study to rigorously replicate and expand upon the outcomes observed in the Mississippi case report,&rdquo; said Dr. Deborah Persaud, the study&rsquo;s lead virologist, who reported the Mississippi case.</p><p>&ldquo;Moving away from reliance on daily ART to control HIV would be a huge improvement to the quality of life of these children,&rdquo; said <a href="https://research.luriechildrens.org/en/researchers/ellen-g-chadwick/" target="_blank" rel="noopener">Dr. Ellen Chadwick</a>, the study&rsquo;s protocol chair, a professor of pediatric infectious diseases at Feinberg School of Medicine, and former director of the section of pediatric, adolescent, and maternal HIV infection at Lurie Children&rsquo;s Hospital of Chicago, via a <a href="https://www.eurekalert.org/news-releases/1036821" target="_blank" rel="noopener">press release.</a></p><h2>Promising Results</h2><p>In this first-of-its-kind study, which enrolled 54 children&mdash;most of whom were international&mdash;6 children were deemed eligible for ART interruption. Four children showed completely undetected HIV for 48 weeks and longer; of those, 3 are still being followed in remission for 48, 52, and 64 weeks, respectively.<strong>&nbsp;</strong>The fourth child experienced remission for 80 weeks before their HIV rebounded to detectable levels.</p><p>&ldquo;This remission was much longer than we had anticipated,&rdquo; Dr. Chadwick said. &ldquo;We&rsquo;re not surprised or crestfallen if they rebound because that&rsquo;s what usually happens when medications are stopped. If we can get the virus to such low levels that we might be able to use some newer, innovative treatments to keep them from needing medication every day, then we&rsquo;re setting them up for success with long-term virologic control.&rdquo;</p></p>


Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Children Born With HIV Surpass 1 Year of Remission After Pausing Therapy

Infectious Disease

Four of 6 children born with HIV who were deemed eligible to have their treatment paused have remained disease free for a year.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe